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ABSTRACT
Objective: The aim of this study was to assess lifestyle behaviour as well as risk factor manage-
ment across Belgian coronary patients who participated in the cross-sectional European Action
on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE) surveys.
Methods: Analyses are based on a series of coronary patients by combining data from the
Belgian participants in the EUROASPIRE III (328 patients; in 2006–2007) and EUROASPIRE IV (343
patients; in 2012–2013) surveys. Four hospitals located in the Ghent area participated in the sur-
veys. Patients included in the analyses were 18 years old and had been hospitalised for a cor-
onary event. Information on cardiovascular risk factors, lifestyle behaviour and medical treatment
were obtained.
Results: Overall, the proportion of smokers was 11% with 40% persistent smokers. Adequate
physical activity levels were reported by 17%, 28% of patients were obese, 47% was central
obese and known diabetes was prevalent in 21% of patients. Hypertension was observed in 46%
of patients and 20% had a total cholesterol5mmol/L. About 80% had participated in a cardiac
rehabilitation programme and the majority of patients were treated with blood pressure (92%)
or lipid-lowering drugs (92%). Anxiety and depressive symptoms were reported by 30% and
24%, respectively. Differences between EUROASPIRE III and IV were limited.
Conclusions: Compared to the overall EUROASPIRE results in Europe, Belgian CHD patients
seem to do slightly better. However, tackling obesity, physical inactivity, hypertension and
psychosocial distress remains an important challenge in the management of coronary patients.
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Life expectancy has increased in most western coun-
tries over the last decades. However, cardiovascular
disease (CVD) remains the leading cause of death
across Europe [1]. In Belgium, CVD accounts for 28.8%
of the total mortality. About 29.5% of all CVD deaths
are due to ischaemic heart disease [2]. In addition to
the mortality burden, CVD is also associated with a
substantial morbidity burden. CVD is the second most
important cause of disability-adjusted life years
(DALYs) in Belgium, with ischaemic heart disease
responsible for 7.1% of DALYs [3].
Several guidelines have been developed over the
last decades, in order to reduce the cardiovascular bur-
den. The European Society of Cardiology (ESC) pub-
lished his first joint guidelines on cardiovascular
prevention in 1994 with regular updates since [4–9]. In
order to assess whether these guidelines are followed
in clinical practice, the EUROASPIRE (European Action
on Secondary Prevention through Intervention to
Reduce Events) surveys were initiated. A first survey
was performed across 9 European countries in
1995–1996 [10]. Since then, three additional
EUROASPIRE surveys took place (EUROASPIRE II in
1999–2000; EUROASPIRE III in 2006–2007; EUROASPIRE
IV in 2012–2013) the latest one included 24 European
countries [11–13]. Overall, the EUROASPIRE surveys
show a suboptimal adherence to lifestyles and an
insufficient risk factor control in coronary patients [14].
In the 3rd and 4th wave of the survey, the interview
and physical measurements were organised in a
strictly comparable way. Several hospitals located in
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the city of Ghent, Belgium, took part in the latest two
surveys. The aim of this study was to analyse the
prevalence of risk factors across these coronary
patients and to assess how the prevention guidelines
have been implemented in clinical practice over the
latest decade.
Methods
Analyses are based on data from the repeated cross-
sectional EUROASPIRE surveys performed in selected
geographical areas [12–13]. All hospitals from the city
of Ghent with cardiology facilities (Ghent University
Hospital, AZ Maria Middelares, AZ Sint-Lucas, AZ Jan
Palfijn), took part in EUROASPIRE III (328 patients; in
2006–2007) and three of them (Ghent University
Hospital, AZ Maria Middelares, AZ Sint-Lucas) in
EUROASPIRE IV (343 patients; in 2012–2013). The
Ghent district has over half a million inhabitants [15].
For each survey, a new sample of coronary patients
was recruited. Patients could only be included once.
Consecutive patients, men and women (between 18
and 80 years at the time of their index event), hospi-
talised for a first or recurrent myocardial infarction,
coronary artery bypass graft surgery, elective or emer-
gency percutaneous coronary intervention or acute
myocardial ischaemia (referred to as index event) were
identified and invited to participate. Patients were
interviewed and examined at least 6 months but no
more than 3 years following the index event, by
trained research staff. Information on personal and
demographic factors, medical and cardiovascular his-
tory, reported lifestyle and risk factor management
was collected.
At the time of the interview, a physical examination
was performed, assessing height and weight (in light
indoor clothes without shoes using a SECA 701/220
[SECA, Hamburg, Germany]), waist circumference,
blood pressure (measured at least twice in sitting pos-
ition with an automatic digital sphygmomanometer,
Omron M5-1 in EUROASPIRE III and Omron M6 in
EUROASPIRE IV [Omron Healthcare, Kyoto, Japan]),
breath carbon monoxide (using a smokerlyzer Bedfont
Scientific Micro 4 in EUROASPIRE III and Bedfont
Scientific Microþ in EUROASPIRE IV [Bedfont Scientific,
Kent, UK]), serum total cholesterol, HDL-cholesterol
and HbA1c in patients with diabetes. Blood analyses
were performed in one central laboratory (National
Institute for Health and Welfare, Helsinki, Finland).
Furthermore, during the interview patients were asked
about their current risk factors including medical man-
agement, diabetes, and smoking. Physical activity lev-
els were assessed by asking patients to describe their
level of activity outside of work using a Likert scale
including the following answer categories: no physical
activity weekly; only light physical activity in most
weeks; vigorous physical activity at least 20min once
or twice a week; vigorous physical activity for at least
20min three or more times a week. In addition,
patients were asked to indicate whether they were
regularly active (e.g. brisk walking, aerobics, jogging,
bicycling, swimming, rowing, etc.) in order to increase
their physical fitness. Furthermore, information on their
medical treatment and attendance to cardiac rehabili-
tation was collected. Psychological distress and self-
perceived health status were measured in using the
hospital anxiety and depressions scale (HADS) [16] –
including seven items on depressive symptoms and
seven items on anxiety symptoms- and the EQ-5D
instrument [17] – consisting of a five-item question-
naire (EQ-5D-3L in EUROASPIRE III and EQ-5D-5L in
EUROASPIRE IV) and a visual analogue scale. The HADS
questionnaire allows to calculate an anxiety (HADS-A)
and depression (HADS-D) score on a scale from 0 to
21. The EQ-5D items result in an index score from 0
(worst health state) to 1 (perfect health), whereas the
VAS ranges from 0 (worst imaginable health state) to
100 (best imaginable health state).
For analytical purposes, risk factor targets were
defined (see Table 1).
Statistical analyses
Descriptive analyses were used to gain knowledge on
the prevalence of risk factors and risk factor manage-
ment. Differences in risk factor prevalence and risk fac-
tor management between EUROASPIRE III and IV were
assessed with binary logistic regression or linear
regression, adjusted for a predefined set of basic
patient characteristics (gender, age and educational
level at index event). All appropriate model assump-
tions were fulfilled, with the exception of the continu-
ous EQ-5D scale because of its ceiling effect. Non-
parametric testing for this variable resulted in similar
outcomes. Type I error due to multiple testing was
accounted for with the Benjamini–Hochberg procedure
by including all variables at once.
Low education was defined as ‘Less than primary
school’ or ‘Primary school completed’; secondary edu-
cation was defined as ‘Secondary school completed’ or
‘High school completed’ or ‘Intermediate between sec-
ondary level (e.g. technical training)’; high education
was defined as ‘College/University completed’ or
‘having obtained a Postgraduate degree’. Significance
levels were set at p< .05 (two-sided). Analyses were
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performed using IBM SPSS version 21 (IBM SPSS
Statistics, Armonk, NY).
Results
In total, information on 671 CHD patients was avail-
able (328 patients took part in EUROASPIRE III and 343
patients in EUROASPIRE IV). Patient characteristics
were comparable across surveys. The mean age was
64.2 (9.5) years and the majority of participants
(85.7%) were males. Revascularisation procedures as
recruiting diagnosis were seen in 87.6% of patients.
Furthermore, 22.3% of patients were low educated
and 23.8% had completed high education.
Physical measurements
Patients had a mean BMI of 28.4 (4.4) kg/m2. The aver-
age waist was 100.2 (12.9) cm in men and 93.6 (15.1)
cm for women. The average blood pressure both sys-
tolic as well as diastolic was significantly lower in EA IV
compared to EA III (138.7 (21.7) and 81.2 (12.2) mmHg
and 132.9 (18.3) and 78.0 (10.7) mmHg, respectively).
Likewise, total cholesterol (from 4.5 to 4.3mmol/L) as
well as LDL-cholesterol (from 2.5 to 2.4mmol/L)
improved significantly from EAIII to EAIV. Finally, the
average HbA1c among patients with diabetes was 6.8%
in EA IV compared with 7.4% in EA III (see Table 2).
Risk factors on target
About 11% of patients are smokers (see Table 3). Of
those patients who were smoking during the month
prior to the index event, 40% is still smoking at the
time of the interview. Also, 28% of patients is obese
and 47% of patients is central obese. Adequate phys-
ical activity levels, performing vigorous physical activ-
ity levels for at least 20min three or more times a
week is seen in 17% of patients. Over the latest two
surveys a significant drop in adequate physical activity
was seen (23% in EAIII and 12% in EAIV). In contrast,
on average 50% of patients indicated to have been
physically active in order to increase their physical fit-
ness (e.g. brisk walking, aerobics, jogging, bicycling,
Table 2. Patient characteristics.
EUROASPIRE EUROASPIRE III EUROASPIRE IV p Value
Age 64.2 (9.5) 62.2 (9.0) 66.1 (9.5) <.001
Males (%) 84% (564/671) 86% (281/328) 83% (283/343) .263
Revascularisation as IE (%) 88% (588/671) 90% (294/328) 86% (294/343) <.001
High education 24% (158/664) 24% (78/323) 23% (80/341) <.001
BMI 28.4 (4.4) 28.2 (4.2) 28.6 (4.6) .246
Waist (men) 100.2 (12.9) 99.7 (11.9) 100.8 (13.8) .300
Waist (women) 93.6 (15.1) 95.2 (12.7) 92.4 (16.8) .363
Systolic blood pressure 135.7 (20.2) 138.7 (21.7) 132.9 (18.3) .001
Diastolic blood pressure 79.5 (11.6) 81.2 (12.2) 77.9 (10.7) <.001
Total cholesterol 4.3 (0.9) 4.5 (0.9) 4.3 (0.9) .008
LDL-cholesterol 2.4 (0.7) 2.5 (0.7) 2.4 (0.7) .011
HbA1c (in diabetes patients) 7.0 (1.4) 7.4 (2.0) 6.8 (1.0) .048
Mean (SD) or %; Unadjusted p-values.
Table 1. Risk factor targets.
Elevated blood pressure Systolic blood pressure 140mmHg or diastolic blood pressure
90mmHg (80mmHg in patients with diabetes) (average of two
readings in standard conditions)
Elevated low density lipoprotein cholesterol (LDL-cholesterol) LDL-cholesterol 2.5mmol/L (100mg/dL)
Elevated total cholesterol (TC) TC-cholesterol 5mmol/L (190mg/dL)
Elevated HbA1c (in patients with diabetes) HbA1c 7.0%
Central obesity Waist circumference 88 cm in women and 102 cm in men
Overweight Body mass index (BMI) 25 kg/m2
Obesity BMI 30 kg/m2
Current smokers Self-reported smoker or CO in breath >10 ppm
Persistent smoking Current smokers who were smoking in the month prior to the index
event
Adequate physical activity level Vigorous physical activity outside work for at least 20min three or
more times a week
Regular exercise Regular physical exercise to increase physical fitness, causing an
increase in breathing rate and causing sweating
Diabetes Self-reported diabetes
Cardiac rehabilitation attended Attending at least half of the advised rehabilitation sessions
Possible anxiety HADS-A 8
Possible depression HADS-D 8
Probable anxiety HADS-A 11
Probable depression HADS-D 11
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swimming, rowing, etc., 3–5 times per week for
20–60min per session) with a small, but significant
increase from 47 to 53% between both surveys.
Furthermore, 21% of patients had diabetes. Overall, an
elevated blood pressure was seen in 46% of patient,
with a significant decrease from 50 to 43% between
the IIIrd and IVth survey. A total cholesterol5mmol/L
was seen in 20% of patients, and 40% of patients had
an LDL-cholesterol2.5mmol/L. The proportion of
patients with an elevated LDL-cholesterol decreased
significantly from 50 to 33%. Finally, 38% of patients
with diabetes had an HbA1c7% (44% in EA III and
35% in EA IV).
Medical treatment and rehabilitation
About 92% of patients was on blood pressure lower-
ing medication (see Table 4), very similar in both sur-
veys. About 95% of patients were on aspirin or
antiplatelet medication, 80% was on beta blockers and
39% on ACE inhibitors. Likewise, 92% of patients was
on lipid-lowering medication, with 91% of patients tak-
ing statins. A significant increase in statin intake was
observed between surveys (88–94%). Cardiac rehabili-
tation (attending more than half of the sessions) was
followed by 80% of patients. A significant increase was
seen between surveys (77–83%).
Psychological distress and self-perceived health
status
Anxiety symptoms were reported by 30% of the
patients and 24% of the patients reported depressive
symptoms (see Table 5). A probable anxiety disorder
(HADS-A11) was seen in 12% of patients and 8.2%
of patients suffered from a probable depression dis-
order (HADS-D11). The mean HADS-A and HADS-D
were 5.7 (3.9) and 4.9 (3.7), respectively. An average
EQ-5D index of 0.80 (0.22) was observed, with a signifi-
cant decrease over time (0.83 (0.22) versus 0.78 (0.21)).
Patients rated their health status on a VAS scale as 73
(15.8) on average.
Significant differences between EUROASPIRE III and
IV remained significant after the Benjamini–Hochberg
Procedure for multiple testing.
Discussion
This manuscript provides an overview of how guide-
lines on secondary prevention are implemented in
Table 3. Prevalence of risk factor on target.
EUROASPIRE EUROASPIRE III EUROASPIRE IV p Value
Risk factor at interview
Smoking 11% (72/669) 13% (44/326) 8% (28/343) .209
Persistent smokersa 40% (65/161) 41% (39/94) 39% (26/67) .540
Obese 28% (187/668) 26% (83/325) 30% (104/343) .260
Central obese 47% (310/663) 46% (147/323) 48% (163/340) .980
Adequate physical activity 17% (112/647) 23% (72/318) 12% (40/329) .018
Regular physical activity 50% (330/659) 47% (149/318) 53% (181/341) .018
Diabetes 21% (137/657) 19% (60/322) 23% (77/335) .576
Elevated blood pressureb 46% (307/661) 50% (162/328) 43% (145/335) .005
Elevated total cholesterolc 20% (111/554) 25% (55/218) 17% (56/336) .051
Elevated LDL-cholesterold 40% (216/546) 50% (107/216) 33% (109/330) .001
Elevated HbA1ce 38% (40/106) 44% (15/34) 35% (25/72) .288
aSmoking in those patients who were smoking one month prior to the index event.
bElevated blood pressure on target: SBP/DBP140/90mmHg (140/80mmHg in patients with diabetes).
cElevated TC on target: TC5mmol/L.
dElevated LDL-cholesterol: LDL-cholesterol2.5mmol/L.
eElevated HbA1c: HbA1c7% in patients with diabetes.
p Values from logistic regression adjusted for age, gender and education.p Value remains significant after Benjamini–Hochberg procedure.
Table 4. Medication and rehabilitation.
EUROASPIRE EUROASPIRE III EUROASPIRE IV p Value
Aspirin or other antiplatelet 95% (632/668) 94% (304/325) 96% (328/343) .108
Beta-blocker 80% (534/668) 80% (260/325) 80% (274/343) .928
ACE inhibitor 39% (260/668) 39% (128/325) 38% (132/343) .767
BP lowering 92% (613/668) 92% (298/325) 92% (315/343) .675
Statin 91% (608/668) 88% (285/325) 94% (323/343) .009
Lipid lowering 92% (613/338) 87% (288/325) 95% (325/343) .012
Cardiac rehabilitation 80% (416/517) 77% (195/252) 93% (221/265) .009
p Values from logistic regression adjusted for age, gender, and education.p Value remains significant after Benjamini–Hochberg procedure.
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Belgian patients with CHD. Combining information
from EUROASPIRE III and IV provides us with a sample
of 671 patients with stable CHD. In this population,
one in 10 patients was a smoker, with about three in
five prior smokers having made a successful smoking
cessation attempt. About 28% of patients are obese
and central obesity was seen in almost half of patients.
Although one in two patients performs regular exer-
cise causing an increase in breathing rate or sweating,
only 17% is adequate physically active according to
the guidelines. Diabetes is reported by 21% of
patients. Slightly more than half of patients have a BP
on target and three in five patients have their LDL-
cholesterol on target. With regard to medication use, a
large majority of patients was on blood pressure low-
ering drugs and on lipid-lowering drugs.
Comparing the Belgian series of CHD patients form
EUROASPIRE III with EUROASPIRE IV revealed by and
large the same results with some exceptions. A signifi-
cant decrease in patients with elevated blood pressure
levels and elevated LDL-cholesterol levels was seen as
well as a significant increase in statin use and cardiac
rehabilitation. These improvements are probably a
reflection of the changes in clinical management as a
response to the updated guidelines with more strin-
gent targets.
The contrasting findings regarding physical activity
levels, with a decrease observed inadequate physical
activity and an increase seen in regular activity might
be caused by the content of the questions included in
the questionnaire. Whereas the former asks about vig-
orous physical activity outside work with four answer
possibilities ranging from no physical activity to vigor-
ous physical activity for at least 20min three or more
times a week, the latter question only provides a yes/
no answer with no further details on the level of phys-
ical activity. Indeed, a closer look at the different
answer possibilities regarding adequate physical activ-
ity revealed a shift from vigorous physical activity in
EAIII to light physical activity in EAIV, which could
mean that more patients are physically active, but
most of them perform only light physical activity.
Compared with the overall results of the latest
EUROASPIRE IV survey including 24 countries (Belgium,
Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus,
Czech Republic, Finland, France, Germany, Greece,
Ireland, Latvia, Lithuania, the Netherlands, Poland,
Romania, Russia, Serbia, Slovenia, Spain, Sweden,
Turkey, Ukraine and the UK) [13], the risk factor man-
agement of Belgian patients corresponds with the
average result. No substantial differences were seen in
the prevalence of risk factors, with the exception of
smoking (EUROASPIRE IV average 16%), obesity
(EUROASPIRE IV average 38%) and central obesity
(EUROASPIRE IV average 58%). Lipid-lowering medica-
tion intake was higher compared to the overall
EUROASPIRE IV result (87% on lipid-lowering
medication).
A comparison with the Belgian results of the earlier
EUROASPIRE II survey (1999–2000) -considering
patients until 71 years old, since that was the upper
age limitation in EUROASPIRE II – revealed a substan-
tial improvement in risk factor prevalence as well as
risk factor management. The prevalence of obesity and
central obesity remained more or less the same as
well as the mean BP values, whereas the proportion of
smokers and patients with elevated LDL cholesterol
more than halved. Medication use increased substan-
tially since 2000, in particular the use of lipid-lowering
medication, mainly the use of statins with only 43% of
patients taking statins in EUROASPIRE II [11]. Notable,
an improvement was seen in the proportion of
patients having an accumulation of risk factors, which
could potentially lead to better long-term outcomes.
In our Belgian sample, possible or probable anxiety
disorders were seen in 30.2%, whereas 25.7% of
patients suffered from a possible or probable depres-
sive disorder. On European level, 26% of patients had
a HADS-A8 and 22% of patients had a HADS-D8.
Problems with anxiety and depression are very com-
mon in coronary patients. Celano et al. found a preva-
lence of depressive feelings ranging between 31 and
45% [18]. Likewise, anxiety symptoms are prevalent in
24–36% of CHD patients [19,20]. The prevalence of
psychological distress is known to be a predictor of
Table 5. Psychological distress and health status.
EUROASPIRE EUROASPIRE III EUROASPIRE IV p Value
HADS-A 8 30% (186/615) 33% (91/273) 28% (95/342) .236
HADS-D 8 24% (146/615) 26% (70/273) 22% (76/342) .191
HADS-A 5.7 (3.91) 5.9 (3.71) 5.5 (4.05) .401
HADS-D 4.9 (3.65) 5.0 (3.86) 4.7 (3.48) .099
EQ-5Da 0.80 (0.22) 0.83 (0.22) 0.78 (0.22) .016
EQ-VAS 73 (15.77) 72 (16.27) 74 (15.36) .214
aEQ-5D-3L was used in EUROASPIRE III and EQ-5D-5L was used in EUROASPIRE IV.
% or mean (SD); p values from regression analyses adjusted for age, gender, and education.p Value remains significant after Benjamini–Hochberg procedure.
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worse coronary outcomes [21]. Doyle et al. have
shown that psychological distress also results in lower
smoking cessation rates in coronary patients, which
support the fact that behavioural changes are more
likely to occur in non-depressed and non-anxious
patients [22]. Regarding the drop in EQ-5D index score
between the latest two surveys, it is important to
notice that in EUROASPIRE III the EQ-5D-3L was used
whereas in EUROASPIRE IV the more sensitive EQ-5D-
5L was included, which could explain the significant
difference between surveys.
The EUROASPIRE surveys make use of standardised
interview and examination procedures performed by
trained personnel. However, there are some limitations
to the study. In the context of these analyses, espe-
cially the external validity of results poses a restriction
on the generalisability of the findings. Since the
Belgian data are drawn from coronary patients in hos-
pitals located in the Ghent area, the results might not
be representative for the entire country. Furthermore,
although statistical adjustment for patient characteris-
tics was performed, patients across surveys might dif-
fer on several other unknown variables which can
have an influence on their risk factor profile. Finally,
much of the information gathered is based on self-
reported data, making the results subject to possible
recall bias and social desirability bias. Also due to
selection bias, it might be that those patients willing
to participate are doing better or behave more exem-
plary with better compliance rates.
In conclusion, compared to the other countries
included in the EUROASPIRE survey, Belgian CHD
patients perform slightly better on several risk factors,
with the exception of anxiety and depression feelings.
However, even considering the more conservative risk
factors, there remains a considerable room for
improvement, in particular with regard to obesity and
central obesity prevalence, hypertension and physical
activity. Clinical treatment of CHD patients should fur-
ther focus on the prevalence of these risk factors.
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